CSF3 and acute myeloid leukemia: Per an AML treatment protocol, the patient received induction chemotherapy but was noted to have 54% blasts at the end of the induction phase with low-dose ADE (cytarabine, daunorubicin, and etoposide) followed by IDA-FLAG (idarubicin, fludarabine, cytarabine, and granulocyte colony-stimulating factor).